Rep. Byron Donalds Buys Eli Lilly and Company (NYSE:LLY) Shares

Representative Byron Donalds (Republican-Florida) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on May 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on April 2nd. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 4/2/2026.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 4/2/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 4/2/2026.
• Purchased $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 3/20/2026.
• Sold $1,001 – $15,000 in shares of Trade Desk (NASDAQ:TTD) on 3/20/2026.
• Purchased $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 3/13/2026.

Eli Lilly and Company Stock Up 2.4%

LLY traded up $23.27 on Tuesday, reaching $1,011.36. 1,667,508 shares of the company traded hands, compared to its average volume of 3,169,157. The company has a market cap of $952.44 billion, a price-to-earnings ratio of 35.91, a PEG ratio of 1.09 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock’s 50 day moving average price is $940.00 and its 200-day moving average price is $999.39. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly completed a key Phase 1 drug-interaction study for olomorasib, helping clarify next steps for its KRAS cancer pipeline and reducing development uncertainty. Eli Lilly Completes Key Olomorasib Drug Interaction Study, Clarifying Next Steps for KRAS Pipeline
• Positive Sentiment: Investors are also encouraged by the continued strength of Lilly’s obesity business, with multiple articles highlighting the company as a leader in the weight-loss drug boom and suggesting the market still sees room for further upside.
• Positive Sentiment: The company will participate in Bernstein’s Strategic Decisions Conference later this month, keeping attention on management’s outlook and pipeline updates. Lilly to participate in Bernstein’s 42nd Annual Strategic Decisions Conference
• Neutral Sentiment: Media coverage comparing Lilly with Novo Nordisk and Viking Therapeutics underscores rising competition in obesity treatments, but does not materially change Lilly’s leadership position yet.
• Negative Sentiment: The U.S. Supreme Court declined to hear Lilly’s appeal in a Medicaid whistleblower case, leaving a roughly $194 million award in place and keeping legal/compliance risk in focus. US Supreme Court turns away Eli Lilly’s challenge to whistleblower law

Wall Street Analyst Weigh In

A number of research firms recently commented on LLY. Scotiabank restated an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Zacks Research lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Rothschild & Co Redburn increased their price objective on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Finally, TD Cowen raised their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,218.33.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC raised its stake in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares during the last quarter. Basso Capital Management L.P. bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $30,000. Finally, 10Elms LLP grew its position in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.